Could a new pill ease borderline personality disorder symptoms?

NCT ID NCT05356013

Completed Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tested whether Caplyta (lumateperone), a drug already used for other mental health conditions, can reduce symptoms of borderline personality disorder (BPD). Sixty adults with BPD received either Caplyta or a placebo pill for 8 weeks. Researchers measured changes in BPD symptom severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Caplyta (lumateperone), an atypical antipsychotic drug
What this could lead to: If it works, this could point toward a new medication option to ease symptoms of borderline personality disorder.
What could go wrong: This is a small, early-phase (Phase 2) study with only 60 participants. The drug may not prove more effective than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE PERSONALITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE PERSONALITY DISORDER

Contacts and locations

Locations

University of Chicago Medical Center

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.